PIK3CA and endometrial cancer: Based on there being neither therapeutic options for paclitaxel-resistant endometrial cancer nor PI3K inhibitors approved in endometrial cancer, we established a preclinical model with paclitaxel-resistant, PIK3CA-mutated endometrial cancer.